Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
|Articles|July 15, 2002
- BioPharm International-07-01-2002
- Volume 15
- Issue 7
Virus Inactivation in the 1990's ? and into the 21st Century. Part 1: Skin, Bone, and Cells
Author(s)Gail Sofer
by Gail Sofer, BioReliance Viruses present dangers (and therefore challenges) to biopharmaceutical manufacturing processes. The virus inactivation method chosen depends on the virus and its surrounding medium. This survey article, organized by sample type, lists viral inactivation methods published during the past decade. Part 1 presents data for skin and bone and for cells that are not platelets or blood cells.
Advertisement
Articles in this issue
about 24 years ago
Facilitating Client Audits: The Contract Laboratory Perspectiveabout 24 years ago
Knowledge Management: The Four Pillars of Successabout 24 years ago
Inside Washington: One Hundred Years of Biotech Regulationabout 24 years ago
Guest Editorial: Supreme Court Rules on FestoAdvertisement
Related to this article
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.
The glucagon/GLP-1 dual agonist hit both weight loss endpoints in phase 3, though gastrointestinal discontinuations and competitor data temper the readout.
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Advertisement
Advertisement